SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 1 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $600 | -53.8% | 1,000 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $1,300 | -26.1% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,760 | -43.9% | 1,000 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $3,140 | -37.2% | 1,000 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $5,000 | +25.0% | 1,000 | 0.0% | 0.00% | +33.3% |
| Q2 2022 | $4,000 | -33.3% | 1,000 | 0.0% | 0.00% | -25.0% |
| Q1 2022 | $6,000 | -25.0% | 1,000 | 0.0% | 0.00% | -20.0% |
| Q4 2021 | $8,000 | -11.1% | 1,000 | 0.0% | 0.01% | -28.6% |
| Q3 2021 | $9,000 | -25.0% | 1,000 | 0.0% | 0.01% | -22.2% |
| Q2 2021 | $12,000 | -7.7% | 1,000 | 0.0% | 0.01% | -10.0% |
| Q1 2021 | $13,000 | -18.8% | 1,000 | 0.0% | 0.01% | -28.6% |
| Q4 2020 | $16,000 | +77.8% | 1,000 | 0.0% | 0.01% | +75.0% |
| Q3 2020 | $9,000 | 0.0% | 1,000 | 0.0% | 0.01% | -20.0% |
| Q2 2020 | $9,000 | +28.6% | 1,000 | -12.5% | 0.01% | +25.0% |
| Q1 2020 | $7,000 | -12.5% | 1,143 | +14.3% | 0.01% | -11.1% |
| Q4 2019 | $8,000 | – | 1,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alexandria Capital, LLC | 1,003,725 | $15,663,000 | 1.66% |
| Golden State Equity Partners | 123,817 | $1,932,000 | 1.33% |
| Rhenman & Partners Asset Management AB | 821,888 | $12,826,000 | 1.05% |
| WASATCH ADVISORS LP | 10,072,381 | $157,180,000 | 0.77% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 29,636 | $462,000 | 0.73% |
| Ceeto Capital Group, LLC | 80,000 | $1,248,000 | 0.63% |
| EMC Capital Management | 48,992 | $765,000 | 0.58% |
| Fort Sheridan Advisors LLC | 71,173 | $1,111,000 | 0.54% |
| Vanguard Capital Wealth Advisors | 34,680 | $584,000 | 0.54% |
| Casdin Capital, LLC | 1,080,000 | $16,853,000 | 0.50% |